Share on LinkedInShare on LinkedIn

ARTICLE · 06 JULY 2023

Obviousness And Written Description Take Down An Infringed Patent

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Azurity Pharms., Inc. v. Alkem Labs. Ltd., 2023 U.S. Dist. LEXIS 22848 (D. Del. Feb. 10, 2023), the district court held that Alkem's ANDA infringes Azurity's asserted claims, but the claims are invalid...

United StatesIntellectual Property

Holdings

In Azurity Pharms., Inc. v. Alkem Labs. Ltd., 2023 U.S. Dist. LEXIS 22848 (D. Del. Feb. 10, 2023), the district court held that Alkem's ANDA infringes Azurity's asserted claims, but the claims are invalid due to lack of written description support and obviousness.

Background

Azurity's claims relate to enalpril formulations. The individual claimed ingredients were known prior in the art. Azurity based its patentability on combining those ingredients into a liquid that would be stable for 12 to 24 months. Id. at *2. Representative claim 4 of the '621 patent reads:

A stable oral liquid formulation, consisting essentially of:

(i) about 0.6 to about 1.2 mg/mL enalapril or a pharmaceutically acceptable salt or solvate thereof;

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from